← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS › ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS › Other antiinflammatory and antirheumatic agents, non-steroids
tenidap
M01AX23
Forms & Strengths
- Not currently marketed; formerly oral capsules (50 mg, 120 mg)
Adult Dosing
- Investigationally evaluated at 120 mg to 240 mg orally once daily for rheumatoid arthritis and osteoarthritis
- Withdrawn from clinical development due to severe toxicity
Pediatric Dosing
- Not evaluated or indicated for pediatric patients
Indications
- Formerly investigated for the treatment of rheumatoid arthritis and osteoarthritis
Mechanism of Action
- Nonsteroidal anti-inflammatory drug (NSAID) with dual inhibition of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX)
- Exhibits disease-modifying antirheumatic drug (DMARD)-like properties in preclinical models
Contraindications
- Hypersensitivity to tenidap or other NSAIDs
- History of active peptic ulcer disease or gastrointestinal bleeding
- Severe hepatic or renal impairment
Adverse Reactions
- Severe gastrointestinal toxicity (ulceration, bleeding, perforation)
- Hepatotoxicity (elevated transaminases, jaundice)
- Nephrotoxicity and fluid retention
- Proteinuria and nephrotic syndrome
- Hypersensitivity reactions and skin rashes
Drug Interactions
- Anticoagulants (increased risk of bleeding)
- Antihypertensives and diuretics (decreased efficacy, increased renal impairment risk)
- Methotrexate (potential for increased toxicity)
- Lithium (decreased renal clearance and increased toxicity)
Curated Content: Needs Vetting Before Put to Clinical Use